Feb 4 2010
Emerging Healthcare Solutions, Inc. (Pink Sheets:EHSI) announced today
that the company has successfully completed the due diligence and review
requirements under their recent option agreement with ThromboVision, a
company that has licensed the patent on the new T-Guide® Platelet
Function Analyzer, which is currently going through regulatory clearance
review.
Successful completion of the due diligence cleared the way for
promulgation of a Term Sheet which was delivered to ThromboVision and
signaled that Emerging Healthcare Solutions conferred confidence in
ThromboVision’s business plan and potential products.
ThromboVision’s new T-Guide® analyzer consists of a desktop instrument
and a disposable test kit that can be located at doctor’s offices and
could become a front line technology that could help prevent heart
attacks, strokes and stent occlusions by directly analyzing a patient’s
platelet status on-site. This new technology should enable doctors to
directly measure platelet status as easily as measuring cholesterol. In
the US, cardiologists and primary care physicians manage 80 million
cardiovascular visits each year, with over 30 million of these patients
on Aspirin or Plavix® platelet therapy.
The emerging healthcare industry is expected to continue steady
expansion, which could be beneficial to many cutting-edge companies such
as Tenet Healthcare Corp. (NYSE: THC), Angeion Corp. (NASDAQ: ANGN),
OccuLogix (NASDAQ: TEAR) and BioMimetic Therapeutics (NASDAQ: BMTI).
Source:
Emerging Healthcare Solutions, Inc.
CHAPPER healthcare, AscellaHealth’s global pharmaceutical distributor, assumes presidency of EUROPACCESS, enhancing access to innovative medicines